Phase I clinical trial of a novel peptide vaccine in combination with UFT/LV for metastatic colorectal cancer

Experimental and Therapeutic Medicine

Volumn 2, Issue 1, 2011, Pages 73-79

  Okuno, Kiyotaka ^a   Sugiura, Fumiaki ^a   Hida, Jin Ichi ^a   Tokoro, Tadao ^a   Ishimaru, Eizaburo ^a   Sukegawa, Yasushi ^a   Ueda, Kazuki ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytotoxic tlymphocytes; Immunochemotherapy; Metastatic colorectal cancer; Peptide vaccine

Indexed keywords

AMINOTRANSFERASE; ASPARAGINYLSERYLGLUTAMINYLPROLYLVALYLTRYPTOPHYLLEUCYLCYSTEINYLLEUCINE; CARRIER PROTEIN; FOLINATE CALCIUM; HLA A2 ANTIGEN; LYSYLLEUCYLARGINYLGLUTAMINYLGLUTAMYLVALYLLYSYLGLUTAMINYLASPARAGINYLLEUCINE; PEPTIDE VACCINE; RING FINGER PROTEIN; UFT; UNCLASSIFIED DRUG;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER SURVIVAL; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; HYPERBILIRUBINEMIA; INJECTION SITE REACTION; KIDNEY DYSFUNCTION; MALAISE; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PATIENT MONITORING; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SURVIVAL RATE; TREATMENT RESPONSE; VACCINATION REACTION;

EID: 78751603860     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.182     Document Type: Article

References (14)

1. Lin YM, Furukawa Y, Tsunoda T, Yue CT, Yang KC and Nakamura Y: Molecular diagnosis of colorectal tumors by expression profiles of 50 genes expressed differentially in adenomas and carcinomas. Oncogene 21: 4120-4128, 2002.
2. Yagyu R, Furukawa Y, Lin YM, Shimokawa T, Yamamura T and Nakamura Y: A novel oncoprotein RNF43 functions in autocrine manner in colorectal cancer. Int J Oncol 25: 1343-1348, 2004.
3. Chewawiwat N, Yano M, Terada M, Hoogenraad NJ and Mori M: Characterization of the novel mitochondrial protein import component, Tom34, in mammalian cells. J Biochem 125: 721-727, 1999.
4. Shimokawa T, Matsushima S, Tsunoda T, Tahara H, Nakamura Y and Furukawa Y: Identification of TOMM34, which shows elevated expression in the majority of human colon cancers, as a novel drug target. Int J Oncol 29: 381-386, 2006.
5. Hattori T, Mine T, Komatsu N, et al: Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 58: 1845-1854, 2009.
6. Uchida N, Tsunoda T, Wada S, Furukawa Y, Nakamura Y and Tahara H: Ring finger protein 43 as a new target for cancer immunotherapy. Clin Cancer Res 10: 8577-8586, 2004.
7. Shirao K, Hoff PM, Ohtsu A, et al: Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 22: 3466-3474, 2004.
8. Kono K, Mizukami Y, Daigo Y, et al: Vaccination with multiple peptides derived from novel cancer-testis antigens can induce specific T-cell responses and clinical responses in advanced esophageal cancer. Cancer Sci 100: 1502-1509, 2009.
9. Correale P, Del Vecchio MT, Genova GD, et al: 5-Fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine. J Natl Cancer Inst 97: 1437-1445, 2005.
10. Correale P, Cusi MG, Tsang KY, et al: Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin-2 induces strong immunologic and antitumor activity in metastatic colon cancer patients. J Clin Oncol 23: 8950-8958, 2005.
11. Nagorsen D and Thiel E: HLAtyping demands for peptide-based 11. anti-cancer vaccine. Cancer Immunol Immunother 57: 1903-1910, 2008.
12. Liu K, Wang C, Chen L, et al: Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A0201 and HLA-A2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin Cancer Res 10: 2645-2651, 2004.
13. Weihrauch MR, Ansen S, Jurkiewicz E et al: Phase I/II combined chemoimmunotherapy with carcinoembryonic antigen-derived HLA-A2-restricted CAP-1 peptide and irinotecan, 5-fluorouracil, and leucovorin in patients with primary metastatic colorectal cancer. Clin Cancer Res 11: 5993-6001, 2005.
14. + T-cell response against MUC-1-derived peptides in gastrointestinal cancer survivors. Cancer Immunol Immunother 54: 750-758, 2005.